Bristol-Myers Squibb Stock
Price
Target price
€40.60
€40.60
-0.600%
-0.245
-0.600%
€67.64
16.05.24 / Tradegate
WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Bristol-Myers Squibb Stock
Bristol-Myers Squibb shows a slight decrease today, losing -€0.245 (-0.600%) compared to yesterday.
Our community is currently high on Bristol-Myers Squibb with 11 Buy predictions and 3 Sell predictions.
With a target price of 67 € there is a hugely positive potential of 65.04% for Bristol-Myers Squibb compared to the current price of 40.6 €.
Our community identified positive and negative aspects for Bristol-Myers Squibb stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Bristol-Myers Squibb stock. On the other hand our users think that "Business model" could be a problem in the future.
Pros and Cons of Bristol-Myers Squibb in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bristol-Myers Squibb vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Bristol-Myers Squibb | -0.600% | -1.157% | -10.662% | -34.206% | -12.511% | -24.022% | -4.482% |
Pfizer Inc. | 0.640% | 2.110% | 9.977% | -21.935% | 1.992% | -19.211% | -25.050% |
Elanco Animal Health Inc. | 0.860% | -3.209% | 21.610% | 98.753% | 15.547% | -45.492% | - |
Biogen Inc. | -2.400% | 3.268% | 15.211% | -25.247% | -10.221% | -8.276% | 2.345% |
Comments
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Bank of America Co. from $72.00 to $68.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $81.00 to $69.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Morgan Stanley from $56.00 to $50.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat